BiotechTube

Nivolumab

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchial Dysplasia

Conditions

Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer

Trial Timeline

Jan 30, 2019 → Dec 31, 2026

NCT ID
NCT03347838

About Nivolumab

Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Bronchial Dysplasia. The current trial status is active. This product is registered under clinical trial identifier NCT03347838. Target conditions include Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer.

What happened to similar drugs?

3 of 16 similar drugs in Bronchial Dysplasia were approved

Approved (3) Terminated (3) Active (10)
✅MontelukastMerckApproved
✅Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
✅Montelukast chewable tablets + Budesonide inhaler + Placebo to montelukast chewable tablets + Placebo to budesonide inhalerOrganonApproved
🔄Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
🔄90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
🔄Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
🔄Test Product + Reference Product + PlaceboAurobindo PharmaPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT03126643Pre-clinicalCompleted
NCT02475382Pre-clinicalCompleted
NCT06523621Phase 2Recruiting
NCT06499298Pre-clinicalCompleted
NCT06735781Pre-clinicalCompleted
NCT06421311Pre-clinicalTerminated
NCT06452329Pre-clinicalCompleted
NCT06003075Phase 2Terminated
NCT06361576Pre-clinicalCompleted
NCT06361563Pre-clinicalCompleted
NCT05068609Pre-clinicalCompleted
NCT04936399Pre-clinicalCompleted
NCT04205409Phase 2Active
NCT04401774Phase 2Completed
NCT04361058Phase 1Withdrawn
NCT04022980Phase 1Completed
NCT04019964Phase 2Completed
NCT04146324Pre-clinicalCompleted
NCT04099251Phase 3Active
NCT03981146Phase 2Active

Competing Products

20 competing products in Bronchial Dysplasia

See all competitors
ProductCompanyStageHype Score
TacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
40
Test Product + Reference Product + PlaceboAurobindo PharmaPhase 3
40
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3
32
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerGlenmark PharmaceuticalsPhase 3
36
Symbicort Turbuhaler + Symbicort pMDI + Pulmicort TurbuhalerAstraZenecaPhase 3
40
RoflumilastAstraZenecaPhase 3
40
RoflumilastAstraZenecaPhase 2/3
38
Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatmentAstraZenecaPhase 3
32
CiclesonideAstraZenecaPhase 3
40
Montelukast plus prednisolone + PrednisoloneMerckPhase 2
35
MontelukastMerckApproved
43
Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
43
inhaled corticosteroid therapyNovartisPhase 1/2
32
PF-00610355 + PF - 00610355 + PF - 00610355PfizerPhase 2
27
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
42
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
42